Presenilin 1 (Psen1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
presenilin-1 (PSEN1) is the catalytic core of the gamma-secretase complex and one of the most important genes in autosomal-dominant early-onset Alzheimer's disease.
Pathogenic PSEN1 variants alter intramembrane cleavage of amyloid precursor protein, shifting peptide profiles toward longer and more aggregation-prone amyloid-beta species
that seed plaque pathology2. Across large mutation registries and family cohorts, PSEN1 mutations are the most common genetic cause of dominantly inherited
Alzheimer's Disease, with onset often in midlife and high but variable penetrance3.
PSEN1 is a multi-pass transmembrane protein that undergoes endoproteolytic processing into N-terminal and C-terminal fragments, which together form the active protease core of
gamma-secretase4. In mature complexes, PSEN1 partners with nicastrin, APH1, and PEN2 to create a membrane-embedded catalytic
environment for regulated cleavage of multiple type-I membrane proteins5. Two conserved aspartates in PSEN1 are
essential for catalysis, and subtle conformational shifts in transmembrane domains influence processive trimming steps that determine C-terminal Amyloid-Beta length
distributions6.
Although APP processing is central in Alzheimer's Disease biology, PSEN1-containing gamma-secretase has broad substrate scope including Notch pathway proteins and synaptic
regulators, which helps explain why variant effects can produce mixed neurodevelopmental, vascular, and neurodegenerative phenotypes7. These pleiotropic
functions also complicate drug development: non-selective gamma-secretase inhibition can impair physiologic signaling, while modulators that shift cleavage preference without fully
blocking activity are being investigated to improve safety8.
PSEN1 has a large mutational spectrum, with hundreds of reported variants and ongoing reclassification as new segregation, biomarker, and functional evidence emerges3. Clinical expression is heterogeneous even within
families, with variability in age at onset, cognitive trajectory, extrapyramidal signs, seizures, spasticity, and cerebral amyloid angiopathy burden9.
Location-specific effects matter: several variants in transmembrane or PAL-motif-adjacent regions strongly perturb processive trimming and favor longer peptides including
A-beta42/A-beta4310.
Recent family- and iPSC-based work has reinforced this mechanistic framework. For example, detailed characterization of PSEN1 P436S supported pathogenicity, atypical presentation,
and increased A-beta43 production, highlighting how mutation-level biochemistry can map onto clinical heterogeneity10. Related work from
autosomal-dominant cohorts also shows that modifier biology, including Apolipoprotein E (APOE and related trial platforms have
shaped endpoint selection, preclinical intervention timing, and translational biomarker strategy14.
Emerging approaches include mutation-informed therapeutic design, selective gamma-secretase modulation, and exploratory gene-therapy strategies aimed at correcting PSEN1-associated
loss-of-function patterns without globally suppressing essential proteolysis17.
Current PSEN1 research emphasizes four converging priorities. First, mutation-resolved functional atlases are being built to link sequence position to quantitative effects on
peptide trimming, substrate selectivity, and cellular stress responses10. Second, multi-omic profiling in
autosomal-dominant tissue and single-cell systems is refining cell-type-specific vulnerability signatures and candidate resilience pathways12.
Third, cohort-level biomarker modeling is improving individualized prognosis and trial stratification, including interaction analyses with [Apolipoprotein E (APOE] background11. Fourth, translational programs continue to test whether early intervention can delay conversion in high-risk carriers before
irreversible network injury accumulates17.
The study of Presenilin 1 (Psen1) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Understanding PSEN1 mutations has driven drug development:
Current AD biomarker research includes:
Immunotherapy approaches:
Disease-modifying approaches:
PSEN1 mutations show:
Phenotypic variability:
Mutation databases: